Seeking Alpha

Sanofi (SNY) Q1 business net income falls to €1.61B (-12% Y/Y), or €1.22 per share,...

Sanofi (SNY) Q1 business net income falls to €1.61B (-12% Y/Y), or €1.22 per share, missing estimates . Revenue falls to €8.1B, missing by €200M . Results reflect the expiration of patents on Plavix and Eloxatin as well as U.S. generic competition for Avapro. All told, generic competition cost the firm more than half a billion euros in the quarter. The company also appoints two new executive committee members.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs